ulipristal and Cytokine-Release-Syndrome

ulipristal has been researched along with Cytokine-Release-Syndrome* in 1 studies

Reviews

1 review(s) available for ulipristal and Cytokine-Release-Syndrome

ArticleYear
[Pharmacovigilance update].
    Revue medicale suisse, 2021, Jan-13, Volume: 17, Issue:720-1

    The main pharmacovigilance updates in 2020 are reviewed. Remdesivir in COVID-19: relatively safe but turns out to be less effective than expected. Hydroxychloroquine in COVID-19 : lack of efficacy and risk of arrhythmias. Cytokines storm in COVID-19: may impact pharmacokinetics. VEGF inhibitors: risk of aneurysm and artery dissection. Tofacitinib: dose-dependant risk of venous thromboembolic events. Ondansetron in the first trimester of pregnancy : a highly debated risk of orofacial cleft defects. Fingolimod : contraindicated during pregnancy due to suspected risk of congenital malformations. Ranitidine: global market withdrawal due to contamination with nitrosamines. Ulipristal for uterine fibroids : market withdrawal due to risk of severe liver injury. Ingenol mebutate : market withdrawal due to paradoxical risk of skin cancers.. Les principales actualités de pharmacovigilance 2020 sont passées en revue. Remdésivir et Covid-19 : moins efficace qu’attendu mais assez sûr. Hydroxychloroquine et Covid-19 : absence d’efficacité et risque d’arythmies. Orage cytokinique et Covid-19 : impact possible sur les paramètres pharmacocinétiques. Inhibiteurs du VEGF : risque d’anévrisme artériel et de dissection. Tofacitinib : risque d’événements thromboemboliques. Ondansétron au 1

    Topics: Adenosine Monophosphate; Alanine; Cleft Lip; Contraindications, Drug; COVID-19 Drug Treatment; Cytokine Release Syndrome; Female; Fingolimod Hydrochloride; Humans; Hydroxychloroquine; Leiomyoma; Norpregnadienes; Pharmacokinetics; Pharmacovigilance; Pregnancy; Ranitidine; Safety-Based Drug Withdrawals; Skin Neoplasms

2021